Review

mouse anti human ceacam5 antibody (Novus Biologicals)

Novus Biologicals is a verified supplier

Novus Biologicals manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Novus Biologicals mouse anti human ceacam5 antibody

<t>CEACAM5</t> expressions in different normal/tumor tissues and DM4 sensitivity in NSCLCs and PDACs. (A) CEACAM5 immunohistochemistry (IHC) of 14 tumor tissues and 14 correspondent normal tissues in tissue microarray (left panel) and quantification values of IHC images (right panel). (B) DM4 response curves in NSCLCs (H1975, A549, H1299, H2030, and H2009 cells) and PDACs (HPAC and HPAF-II cells). Normalized % cell viability (ATP level) was calculated by normalizing luminescence values using buffer (DMSO)-treated respective cells. Results are shown as the mean ±SD for representative data from three independent experiments.

Mouse Anti Human Ceacam5 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+ceacam5+antibody/CEACAM5%2FCD66e+Antibody+(CB30)+-+BSA+Free/pmc10010383-42-20-24
Average 92 stars, based on 1 article reviews

mouse anti human ceacam5 antibody - by Bioz Stars, 2026-09

92/100 stars

Images

1) Product Images from "Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates"

Article Title: Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

Journal: Frontiers in Oncology

doi: 10.3389/fonc.2023.1124039

CEACAM5 expressions in different normal/tumor tissues and DM4 sensitivity in NSCLCs and PDACs. (A) CEACAM5 immunohistochemistry (IHC) of 14 tumor tissues and 14 correspondent normal tissues in tissue microarray (left panel) and quantification values of IHC images (right panel). (B) DM4 response curves in NSCLCs (H1975, A549, H1299, H2030, and H2009 cells) and PDACs (HPAC and HPAF-II cells). Normalized % cell viability (ATP level) was calculated by normalizing luminescence values using buffer (DMSO)-treated respective cells. Results are shown as the mean ±SD for representative data from three independent experiments.

Figure Legend Snippet: CEACAM5 expressions in different normal/tumor tissues and DM4 sensitivity in NSCLCs and PDACs. (A) CEACAM5 immunohistochemistry (IHC) of 14 tumor tissues and 14 correspondent normal tissues in tissue microarray (left panel) and quantification values of IHC images (right panel). (B) DM4 response curves in NSCLCs (H1975, A549, H1299, H2030, and H2009 cells) and PDACs (HPAC and HPAF-II cells). Normalized % cell viability (ATP level) was calculated by normalizing luminescence values using buffer (DMSO)-treated respective cells. Results are shown as the mean ±SD for representative data from three independent experiments.

Techniques Used: Immunohistochemistry, Microarray

in vitro cell killing activities of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 S cells. (A) Cell surface CEACAM5 expression levels in DM4 S NSCLCs (H1299, H1299-CEACAM5, A549, and A549-CEACAM5 cells) and PDACs (HPAC and HPAF-II cells). (B, D) Cell killing activities with ADC SAR408701 analog against DM4 S NSCLCs (H1299, H1299-CEACAM5, and A549, A549-CEACAM5 cells) (B) and DM4 S PDACs (HPAC, and HPAF-II cells) (D) . Normalized % cell viability (ATP level) was calculated by normalizing luminescence values using vehicle (buffer)-treated respective cells. The IC 50 were then determined by nonlinear regression plot of percent specific cytotoxicity versus Log10 concentration of ADC SAR408701 analog using GraphPad Prism software. (C, E) Cytotoxic activities (%) of anti-CEACAM5 CAR-T cells against DM4 S NSCLCs (C) and PDACs (E) . Significance was tested using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001; **, P <0.01; *, P <0.05; versus control T at each E:T ratio. (B–E) Results are shown as the mean ±SD for representative data from three independent experiments.

Figure Legend Snippet: in vitro cell killing activities of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 S cells. (A) Cell surface CEACAM5 expression levels in DM4 S NSCLCs (H1299, H1299-CEACAM5, A549, and A549-CEACAM5 cells) and PDACs (HPAC and HPAF-II cells). (B, D) Cell killing activities with ADC SAR408701 analog against DM4 S NSCLCs (H1299, H1299-CEACAM5, and A549, A549-CEACAM5 cells) (B) and DM4 S PDACs (HPAC, and HPAF-II cells) (D) . Normalized % cell viability (ATP level) was calculated by normalizing luminescence values using vehicle (buffer)-treated respective cells. The IC 50 were then determined by nonlinear regression plot of percent specific cytotoxicity versus Log10 concentration of ADC SAR408701 analog using GraphPad Prism software. (C, E) Cytotoxic activities (%) of anti-CEACAM5 CAR-T cells against DM4 S NSCLCs (C) and PDACs (E) . Significance was tested using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001; **, P <0.01; *, P <0.05; versus control T at each E:T ratio. (B–E) Results are shown as the mean ±SD for representative data from three independent experiments.

Techniques Used: In Vitro, Expressing, Concentration Assay, Software, Control

in vitro cell cytotoxicity assay of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 R cells. (A) Cell surface CEACAM5 expression levels in DM4 R NSCLCs (H1975, H1975-CEACAM5, H2009, and H2009-CEACAM5 cells). (B) Cell killing activities with ADC SAR408701 analog against CEACAM5-positive DM4 R cell lines (H1975-CEACAM5 and H2009-CEACAM5 cells) and CEACAM5-negative DM4 R cell lines (H1975 and H2009 cells). Normalized % cell viability (ATP level) was calculated by normalizing luminescence values for vehicle (buffer)-treated respective cells. (C) Cytotoxic activities (%) of anti-CEACAM5 CAR-T cells against CEACAM5-positive and CEACAM5-negative DM4 R NSCLC cells. Significance was tested using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001; versus control T at each E:T ratio. (B, C) Results are shown as the mean ±SD for representative data from three independent experiments.

Figure Legend Snippet: in vitro cell cytotoxicity assay of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 R cells. (A) Cell surface CEACAM5 expression levels in DM4 R NSCLCs (H1975, H1975-CEACAM5, H2009, and H2009-CEACAM5 cells). (B) Cell killing activities with ADC SAR408701 analog against CEACAM5-positive DM4 R cell lines (H1975-CEACAM5 and H2009-CEACAM5 cells) and CEACAM5-negative DM4 R cell lines (H1975 and H2009 cells). Normalized % cell viability (ATP level) was calculated by normalizing luminescence values for vehicle (buffer)-treated respective cells. (C) Cytotoxic activities (%) of anti-CEACAM5 CAR-T cells against CEACAM5-positive and CEACAM5-negative DM4 R NSCLC cells. Significance was tested using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001; versus control T at each E:T ratio. (B, C) Results are shown as the mean ±SD for representative data from three independent experiments.

Techniques Used: In Vitro, Cytotoxicity Assay, Expressing, Control

in vivo anti-tumor activities of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 S and DM4 R NSCLC tumors. (A) Schematic representation of experimental design and treatment schedule for mice studies. (B, D, F) Tumor growth curve (left panels) and individual mice curves (right panels) of DM4 S A549-CEACAM5 (B) , DM4 R H1975-CEACAM5 (D) , and CEACAM5-negative DM4 S A549 (F) tumors. Significance was analyzed by comparing the tumor volume (mm 3 ) ±SD at endpoint of 1.0 cm 3 (B) or end day ( D, F ) and determined using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001. (C, E, G) Survival curve showing the efficacy of the ADC SAR408701 analog and CAR-T cells in NSG mice. Tumor volume (mm 3 ) are shown as mean ±SD for n=6 or 7 per group. Survival was presented by Kaplan-Meier plot of percentage of mice with tumor volume ≥ 1-1.5 cm 3 . Significance was determined by log-rank (Mantel-Cox) test. ***, P <0.001; **, P <0.01.

Figure Legend Snippet: in vivo anti-tumor activities of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 S and DM4 R NSCLC tumors. (A) Schematic representation of experimental design and treatment schedule for mice studies. (B, D, F) Tumor growth curve (left panels) and individual mice curves (right panels) of DM4 S A549-CEACAM5 (B) , DM4 R H1975-CEACAM5 (D) , and CEACAM5-negative DM4 S A549 (F) tumors. Significance was analyzed by comparing the tumor volume (mm 3 ) ±SD at endpoint of 1.0 cm 3 (B) or end day ( D, F ) and determined using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001. (C, E, G) Survival curve showing the efficacy of the ADC SAR408701 analog and CAR-T cells in NSG mice. Tumor volume (mm 3 ) are shown as mean ±SD for n=6 or 7 per group. Survival was presented by Kaplan-Meier plot of percentage of mice with tumor volume ≥ 1-1.5 cm 3 . Significance was determined by log-rank (Mantel-Cox) test. ***, P <0.001; **, P <0.01.

Techniques Used: In Vivo

Image Search Results

Journal: Frontiers in Oncology

Article Title: Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

doi: 10.3389/fonc.2023.1124039

Figure Lengend Snippet: CEACAM5 expressions in different normal/tumor tissues and DM4 sensitivity in NSCLCs and PDACs. (A) CEACAM5 immunohistochemistry (IHC) of 14 tumor tissues and 14 correspondent normal tissues in tissue microarray (left panel) and quantification values of IHC images (right panel). (B) DM4 response curves in NSCLCs (H1975, A549, H1299, H2030, and H2009 cells) and PDACs (HPAC and HPAF-II cells). Normalized % cell viability (ATP level) was calculated by normalizing luminescence values using buffer (DMSO)-treated respective cells. Results are shown as the mean ±SD for representative data from three independent experiments.

Article Snippet: For immunohistochemistry, the tissue slide was blocked with 10% normal horse serum for 1 h at 25°C and incubated with mouse anti-human CEACAM5 antibody (Novus biologicals, NB11058734, 1:100) for overnight at 4°C in humidified chamber.

Techniques: Immunohistochemistry, Microarray

Journal: Frontiers in Oncology

Article Title: Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

doi: 10.3389/fonc.2023.1124039

Figure Lengend Snippet: in vitro cell killing activities of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 S cells. (A) Cell surface CEACAM5 expression levels in DM4 S NSCLCs (H1299, H1299-CEACAM5, A549, and A549-CEACAM5 cells) and PDACs (HPAC and HPAF-II cells). (B, D) Cell killing activities with ADC SAR408701 analog against DM4 S NSCLCs (H1299, H1299-CEACAM5, and A549, A549-CEACAM5 cells) (B) and DM4 S PDACs (HPAC, and HPAF-II cells) (D) . Normalized % cell viability (ATP level) was calculated by normalizing luminescence values using vehicle (buffer)-treated respective cells. The IC 50 were then determined by nonlinear regression plot of percent specific cytotoxicity versus Log10 concentration of ADC SAR408701 analog using GraphPad Prism software. (C, E) Cytotoxic activities (%) of anti-CEACAM5 CAR-T cells against DM4 S NSCLCs (C) and PDACs (E) . Significance was tested using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001; **, P <0.01; *, P <0.05; versus control T at each E:T ratio. (B–E) Results are shown as the mean ±SD for representative data from three independent experiments.

Techniques: In Vitro, Expressing, Concentration Assay, Software, Control

Journal: Frontiers in Oncology

Article Title: Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

doi: 10.3389/fonc.2023.1124039

Figure Lengend Snippet: in vitro cell cytotoxicity assay of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 R cells. (A) Cell surface CEACAM5 expression levels in DM4 R NSCLCs (H1975, H1975-CEACAM5, H2009, and H2009-CEACAM5 cells). (B) Cell killing activities with ADC SAR408701 analog against CEACAM5-positive DM4 R cell lines (H1975-CEACAM5 and H2009-CEACAM5 cells) and CEACAM5-negative DM4 R cell lines (H1975 and H2009 cells). Normalized % cell viability (ATP level) was calculated by normalizing luminescence values for vehicle (buffer)-treated respective cells. (C) Cytotoxic activities (%) of anti-CEACAM5 CAR-T cells against CEACAM5-positive and CEACAM5-negative DM4 R NSCLC cells. Significance was tested using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001; versus control T at each E:T ratio. (B, C) Results are shown as the mean ±SD for representative data from three independent experiments.

Techniques: In Vitro, Cytotoxicity Assay, Expressing, Control

Journal: Frontiers in Oncology

Article Title: Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

doi: 10.3389/fonc.2023.1124039

Figure Lengend Snippet: in vivo anti-tumor activities of the ADC SAR408701 analog and CAR-T cells targeting CEACAM5 in DM4 S and DM4 R NSCLC tumors. (A) Schematic representation of experimental design and treatment schedule for mice studies. (B, D, F) Tumor growth curve (left panels) and individual mice curves (right panels) of DM4 S A549-CEACAM5 (B) , DM4 R H1975-CEACAM5 (D) , and CEACAM5-negative DM4 S A549 (F) tumors. Significance was analyzed by comparing the tumor volume (mm 3 ) ±SD at endpoint of 1.0 cm 3 (B) or end day ( D, F ) and determined using one-way ANOVA, followed by the tukey’s multiple post hoc test. ****, P <0.0001; ***, P <0.001. (C, E, G) Survival curve showing the efficacy of the ADC SAR408701 analog and CAR-T cells in NSG mice. Tumor volume (mm 3 ) are shown as mean ±SD for n=6 or 7 per group. Survival was presented by Kaplan-Meier plot of percentage of mice with tumor volume ≥ 1-1.5 cm 3 . Significance was determined by log-rank (Mantel-Cox) test. ***, P <0.001; **, P <0.01.

Techniques: In Vivo

FIGURE 3 Expression of each subtype of CEACAM on SSc monocytes. (A-D) Dot plots show the proportion of positivity of CEACAM1 (A), CEACAM3 (B), CEACAM5 (C), and CEACAM6 (D) on CD14+CD16- classical monocytes from HCs and patients with RA and SSc. P values were calculated using a Mann–Whitney U test. **P < 0.01, ***P < 0.001. ns, not signiﬁcant.

Journal: Frontiers in immunology

Article Title: CEACAM 1, 3, 5 and 6 -positive classical monocytes correlate with interstitial lung disease in early systemic sclerosis.

doi: 10.3389/fimmu.2022.1016914

Figure Lengend Snippet: FIGURE 3 Expression of each subtype of CEACAM on SSc monocytes. (A-D) Dot plots show the proportion of positivity of CEACAM1 (A), CEACAM3 (B), CEACAM5 (C), and CEACAM6 (D) on CD14+CD16- classical monocytes from HCs and patients with RA and SSc. P values were calculated using a Mann–Whitney U test. **P < 0.01, ***P < 0.001. ns, not signiﬁcant.

Article Snippet: Flow cytometry and cell sorting To analyze the proportion of CEACAM+ monocytes, peripheral blood mononuclear cells (PBMCs) were separated by Lymphoprep (STEMCELL Technologies) and stained with the following antibodies according to the manufacturer’s instructions: anti CD14-APC (Clone M5E2, BioLegend #301808), CD16-FITC (Clone 3GB, BioLegend #302006), CD56-Percp/Cy5.5 (Clone HCD56, BioLegend #318322), CEACAM-BV421 (Clone B1.1/ CD66, BD Biosciences #562741), CEACAM1-PE (Clone 283340, R&D Systems #FAB2244P), CEACAM3-PE (Clone 06, Sino Biological #11933-H08), CEACAM5-FITC (Clone C365D3, BioRad #MCA1744FT), and CEACAM6-APC (Clone 439424, R&D Systems #MAB3934-SP).

Techniques: Expressing, MANN-WHITNEY

Review

Structured Review

Images

1) Product Images from "Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates"

Similar Products

Image Search Results